Trastuzumab deruxtecan: all 123 studies that test it

Page 1 of 2. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingNCT07836257Phase 2
• Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
• Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerNot yet recruitingNCT07785856Phase 1/2
• A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast CancerNot yet recruitingNCT07782086Not applicable
• A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal CancerNot yet recruitingNCT07691489Phase 2
• T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3
• Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer StudyRecruitingNCT07647016Phase 2
• Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07619521Phase 1/2
• Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast CancerNot yet recruitingNCT07619365Phase 2
• Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast CancersNot yet recruitingNCT07553390Phase 1
• Megestrol Acetate for Fatigue Management in T-DXd Treated Breast CancerRecruitingNCT07543536Phase 3
• A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerRecruitingNCT07497386Phase 2
• HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term RemissionRecruitingNCT07459673Phase 2
• Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesNot yet recruitingNCT07454668Phase 1
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.RecruitingNCT07407465Phase 2
• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2
• Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementRecruitingNCT07371585Phase 2
• Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast CancerNot yet recruitingNCT07368543Phase 2
• Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor TherapyRecruitingNCT07340164Phase 2
• ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
• A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer PatientsRecruitingNCT07281001Not applicable
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerRecruitingNCT07198724Phase 1/2
• Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingNCT07151586Phase 2
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingNCT07137416Phase 1
• Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesRecruitingNCT07134153Phase 1/2
• Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI CancersNot yet recruitingNCT07126561Phase 2
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingNCT07069712Phase 2
• Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial CancerRecruitingNCT07022483Phase 3
• A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsRecruitingNCT07015697Phase 1
• Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT07012031Phase 1/2
• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingNCT06989112Phase 3
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Phase 3
• A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer PatientsRecruitingNCT06832202Phase 2
• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)RecruitingNCT06819007Phase 3
• Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast CancerNot yet recruitingNCT06797622Phase 2
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingNCT06764875Phase 3
• Trial of Trastuzumab Deruxtecan in Previously Treated HER2RecruitingNCT06750484Phase 2
• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3
• A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingNCT06643585Phase 3
• Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingNCT06630130Phase 2
• Castrate Resistant Prostate Cancer Enhertu TherapyRecruitingNCT06610825Phase 2
• T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingNCT06548178Phase 2
• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruitingNCT06533826Phase 2
• EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsRecruitingNCT06525298Phase 1/2
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingNCT06486883Phase 2
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingNCT06467357Phase 3
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerRecruitingNCT06331169Phase 1
• HCQ+ADC vs ADC in the Treatment of Advanced Breast CancerRecruitingNCT06328387Phase 1/2
• Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingNCT06311214Phase 2
• Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesEnrolling by invitationNCT06250777Phase 2
• Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer TrialNot yet recruitingNCT06245824Phase 4
• A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)RecruitingNCT06174987Phase 3
• Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerRecruitingNCT06085755Phase 1/2
• Trastuzumab Deruxtecan (T-DXd) for People With Brain CancerRecruitingNCT06058988Phase 2
• Basket Study for Oligo-metastatic Breast CancerRecruitingNCT05982678Phase 2
• Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal CancerRecruitingNCT05965479Phase 2
• T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low PatientsNot yet recruitingNCT05953168Phase 2
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerRecruitingNCT05950945Phase 3
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingNCT05900206Phase 2
• T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingNCT05894824Phase 1/2
• PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)RecruitingNCT05824975Phase 1/2
• TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingNCT05795101Phase 2
• NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerRecruitingNCT05704829Phase 2
• Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 2
• An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain MetastasisRecruitingNCT05376878Phase 4
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingNCT05372614Phase 1
• Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer PatientsRecruitingNCT05274048Phase 1
• Scalp Cooling in MBCRecruitingNCT04986579Phase 2
• Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingNCT04616560Phase 2
• Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingNCT04585958Phase 1
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+PertuzumabTerminatedNCT05744375Phase 2Results posted
• A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCActive, not recruitingNCT05246514Phase 2Results posted
• Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive, not recruitingNCT05113251Phase 3Results posted
• Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior RegimensCompletedNCT04989816Phase 2Results posted
• Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal CancerCompletedNCT04744831Phase 2Results posted
• A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerActive, not recruitingNCT04739761Phase 3Results posted
• Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT04644237Phase 2Results posted
• A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating MutationsActive, not recruitingNCT04639219Phase 2Results posted
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerCompletedNCT04539938Phase 2Results posted
• Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerActive, not recruitingNCT04494425Phase 3Results posted
• DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] DiseaseCompletedNCT04420598Phase 2Results posted
• DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)CompletedNCT04014075Phase 2Results posted
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedNCT03734029Phase 3Results posted
• DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedNCT03529110Phase 3Results posted
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedNCT03523585Phase 3Results posted
• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminatedNCT03505710Phase 2Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)CompletedNCT03384940Phase 2Results posted
• Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompletedNCT03383692Phase 1Results posted
• DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) ProteinCompletedNCT03368196Phase 1Results posted
• Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerCompletedNCT03366428Phase 1Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]CompletedNCT03329690Phase 2Results posted
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)TerminatedNCT03248492Phase 2Results posted

← Trastuzumab deruxtecan overview